



Mini-review

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

Donatella Aldinucci ^{*}, Marta Celegato, Naïke Casagrande

Department of Experimental Oncology 2, CRO Aviano National Cancer Institute, Aviano, Italy

ARTICLE INFO

Keywords:

Hodgkin lymphoma
Tumor microenvironment
Immune-escape
Angiogenesis
Drug-resistance

ABSTRACT

Classical Hodgkin lymphoma (cHL) is characterized by few tumor cells surrounded by immune cells, fibroblasts, specialized mesenchymal stromal cells and endothelial cells, representing together with their products an active part of the disease.

Hodgkin and Reed–Sternberg (HRS) cells can secrete cytokines/chemokines and angiogenic factors capable of recruiting and/or inducing the proliferation of the surrounding cells and can also interact with distant sites of the microenvironment by secreting exosomes. To escape from a useful anti-tumor response due to the recognition by T and NK cells, HRS cells down-regulate HLA molecules, produce immune suppressive cytokines that inhibit cytotoxic responses, and induce an immunosuppressive phenotype on T lymphocytes and Monocytes. HRS cells survive, proliferate and are protected from the cytotoxic effects of chemotherapy agents by soluble factors or by the direct contact with inflammatory and stromal cells of the tumor microenvironment (TME).

A summary of the current knowledge about classical Hodgkin Lymphoma focusing on the cross-talk between tumor cells and the microenvironment leading to immune-escape, angiogenesis tumor growth/survival and drug resistance will be reviewed here.

© 2015 Elsevier Ireland Ltd. All rights reserved.

General background

Hodgkin Lymphoma (HL) first involves lymph nodes [1]. It is characterized by a minority of tumor cells (less than 1% of the total cell population), collectively termed Hodgkin and Reed–Sternberg (HRS) cells, representing the small, mono-nucleated Hodgkin (H) cells and the large, binucleated or multi-nucleated Reed–Sternberg (RS) cells [2,3] embedded in an inflammatory microenvironment.

HL has been divided into classical HL (cHL), which accounts for 95% of all cases, and the less frequent nodular lymphocyte predominant HL form (NLP HL), considered a different disease.

Although originating from B-lymphoid cells, HRS cells have lost their B cell-phenotype and show a very unusual co-expression of markers characteristic for other hematopoietic lineages [4,5]. HRS cells are characterized by the constitutive activation of nuclear factor kappa B (NF-κB), the Activator Protein-1 (AP-1), the deregulation of lineage-specific transcription factors such as E2A [5], and the Interferon regulating factor (IRF)5 that, together with NF-κB activation, seems to determine the inflammatory phenotype of HRS cells [6]. HRS cells express CD30 and CD40, two members of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family, and

in the majority of cases CD15 (75–85%) and IRF4 [5]. CD20 is positive in approximately 30–40% of cases.

Epstein–Barr virus (EBV) is causally associated with approximately one third of cases in socioeconomically developed countries, while in pediatric HL in Central and South America, the association can be up to 90% [7]. In patients with AIDS, EBV-infected HRS cells are present in nearly all cases [8].

According to World Health Organization, four histological subtypes of cHL have been distinguished based on HRS morphology and microenvironment composition: nodular sclerosis (~80% of cases), mixed cellularity (~15%), the less common lymphocyte-rich cHL and lymphocyte-depleted cHL [9].

Clinical and preclinical evidence suggests that HRS cells need the presence of a protective microenvironment to survive. For example, when HRS cells metastasize into non-lymphoid organs they need to rebuild their peculiar microenvironment. In addition, consistent with the low number of HRS cells with respect to normal cells in tumors, the prognostic significance of positron emission tomography (PET) positivity, used to determine the stage of cHL, seems to be related to the reduction of the microenvironment rather than of tumor cells [10].

Thus, tumor microenvironment (TME) interactions in cHL and their role in promoting tumor growth, immune escape and drug resistance were and will be the topic of numerous studies since they may suggest new prognostic factors and therapeutic approaches.

^{*} Corresponding author. Tel.: +39 0434659234; fax: +39 0434659428.
E-mail address: daldinucci@cro.it (D. Aldinucci).

Download English Version:

<https://daneshyari.com/en/article/10901044>

Download Persian Version:

<https://daneshyari.com/article/10901044>

[Daneshyari.com](https://daneshyari.com)